Literature DB >> 1466987

Vaccine studies with the 32H reisolate of SIVmac251: an overview.

M Cranage1, J Stott, K Mills, T Ashworth, F Taffs, G Farrar, L Chan, M Dennis, P Putkonen, G Biberfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1466987     DOI： 10.1089/aid.1992.8.1479

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  4 in total

1.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

Authors:  E G Hulskotte; A M Geretti; K H Siebelink; G van Amerongen; M P Cranage; E W Rud; S G Norley; P de Vries; A D Osterhaus
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

2.  Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

Authors:  L O Arthur; J W Bess; R G Urban; J L Strominger; W R Morton; D L Mann; L E Henderson; R E Benveniste
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection.

Authors:  M-D Salha; R Cheynier; R Halwani; H McGrath; T Y Langaee; B Yassine Diab; J Fournier; M Parenteau; J Edgar; D Ko; A Sherring; D Bogdanovic; R-P Sekaly; E W Rud
Journal:  Virology       Date:  2008-08-01       Impact factor: 3.616

4.  Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.

Authors:  J D Reeves; S Hibbitts; G Simmons; A McKnight; J M Azevedo-Pereira; J Moniz-Pereira; P R Clapham
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.